Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models

Janie Robert, Manon Feuillolay, María Temple-Llavero, Reginald Florian Akossi, Vanessa Mhanna, Mustapha Cheraï, Gwladys Fourcade, Frédéric Charlotte, Nicolas Tchitchek, Tian Mi, Benjamin Youngblood, Thomas Vazquez, Michelle Rosenzwajg and David Klatzmann ()
Additional contact information
Janie Robert: Immunology-Immunopathology-Immunotherapy (i3)
Manon Feuillolay: Immunology-Immunopathology-Immunotherapy (i3)
María Temple-Llavero: Immunology-Immunopathology-Immunotherapy (i3)
Reginald Florian Akossi: Immunology-Immunopathology-Immunotherapy (i3)
Vanessa Mhanna: Immunology-Immunopathology-Immunotherapy (i3)
Mustapha Cheraï: Hôpital Pitié-Salpêtrière
Gwladys Fourcade: Immunology-Immunopathology-Immunotherapy (i3)
Frédéric Charlotte: Hôpital Pitié-Salpêtrière
Nicolas Tchitchek: Immunology-Immunopathology-Immunotherapy (i3)
Tian Mi: St. Jude Children’s Research Hospital
Benjamin Youngblood: St. Jude Children’s Research Hospital
Thomas Vazquez: 10 rue des Reculettes
Michelle Rosenzwajg: Immunology-Immunopathology-Immunotherapy (i3)
David Klatzmann: Immunology-Immunopathology-Immunotherapy (i3)

Nature Communications, 2025, vol. 16, issue 1, 1-17

Abstract: Abstract Regulatory T (Treg)-based cell therapy holds promise for autoimmune and inflammatory diseases, yet challenges remain regarding the functional stability and persistence of transferred Tregs. Here we engineer Tregs to express a partial agonist form of IL-2 (IL-2pa) to enhance persistence while avoiding toxicity from excessive signaling. Mouse Tregs expressing wild-type IL-2 (Tregs-IL2wt) have only a transient growth advantage, limited by toxicity from likely excessive signaling. By contrast, mouse Tregs-IL2pa exhibit sustained expansion, long-term survival in immunocompetent mice for over a year, and bystander expansion of endogenous Tregs. Tregs-IL2pa maintain a stable activated phenotype, Treg-specific demethylation, and a diverse TCR repertoire. In vivo, prophylactic transfer of Tregs-IL2pa ameliorates multi-organ autoimmunity in a Treg depletion-induced mouse autoimmune model. Lastly, compared with control Treg, human Tregs-IL2pa show enhanced survival in the IL-2-depleted environment of immune-deficient mice and improved control of xenogeneic graft-versus-host disease. Our results thus show that IL-2pa self-sufficiency enhances the stability, durability and efficacy of Treg therapies in preclinical settings.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60082-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60082-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60082-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().